Dramatic improvement in Down Syndrome-associated cognitive impairment with donepezil

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 563-566

  Kondoh, Tatsuro ^a   Amamoto, Nagisa ^a   Doi, Tomoki ^a   Hamada, Hitomi ^a   Ogawa, Yoji ^a   Nakashima, Mikiro ^a   Sasaki, Hitoshi ^a   Aikawa, Katsuyo ^b   Tanaka, Tatsuhiko ^c   Aoki, Mizue ^b   Harada, Junji ^b   Moriuchi, Hiroyuki ^d  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Kakunan School for the Handicapped   (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Donepezil; Down syndrome; Quality of life

Indexed keywords

DONEPEZIL;

ADULT; AGITATION; ARTICLE; CASE REPORT; COGNITIVE DEFECT; DIARRHEA; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; QUALITY OF LIFE; URINE INCONTINENCE; VIOLENCE;

ADULT; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DOWN SYNDROME; FEMALE; HUMANS; INDANS; MALE; MENTAL RETARDATION; PIPERIDINES; QUALITY OF LIFE;

EID: 13944282514     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E427     Document Type: Article

References (20)

1. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-9.
2. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis Down syndrome. Ann Neurol 1985;18:310-3.
3. Kish SJ, Distefano LM, Dozic S, Robitaille Y, Rajput A, Deck JH, et al. [3H] vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 1990;117:347-52.
4. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 1996;93:13333-8.
5. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. Cholinergic therapy for Down's syndrome (letter). Lancet 1999;353:1064-5.
6. Kanno A. Adolescents with Down syndrome showing a rapid regression. Jap J Spec Educ 1997;34:69-75.
7. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am J Psychiatry 1999;156:1470.
8. Kishnani PS, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR. Donepezil for Down's syndrome (letter). Am J Psychiatry 2001;158:143.
9. Prasher VP, Huxley A, Haque MS, the Down Syndrome Aging Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-pilot study. Int J Geriatr Psychiatry 2002;17:270-8.
10. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 2002;59:1133-6.
11. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet 2003;116:111-6.
12. Prasher VP, Adams C, Holder R, the Down Syndrome Research Group. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry 2003;18:549-51.
13. Cipriani G, Bianchetti A, Trabucchi M. Donepezil use in the treatment of dementia associated with Down syndrome (letter). Arch Neurol 2003;60:292.
14. Margallo-Lana ML, Ballard C, Morris C, Kay D, Tyrer S, Moore B. Cognitive decline in Down syndrome (letter). Arch Neurol 2003;60:1024.
15. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 2003;108:367-72.
16. Kishnani PS, Sullivan JA, Spiridigliozzi GA, Heller JH, Crissman BG. Donepezil use in Down syndrome. Arch Neurol 2004;61:605-6.
17. Prasher VP. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry 2004;19:509-15.
18. Huxley A, Prasher VP, Haque MS. The dementia scale for Down's syndrome. J Intellect Disabil Res 2000;44:697-8.
19. Fowler AE. Determinants or rate of language growth in children with DS. In: Nadel L, ed. The psychobiology of Down syndrome. Cambridge, MA: MIT Press, 1988:217-45.
20. Data on file. Eizai Co., Ltd., Tokyo, Japan.